bioAffinity, Philips, and 4DMedical Partner to Advance Veteran Lung Health Screening
Event summary
- bioAffinity Technologies, Philips, and 4DMedical will host a webinar on July 21, 2026, to discuss lung health screening for U.S. veterans.
- The event will feature clinical experts addressing challenges in identifying and managing lung disease in veteran populations, including those impacted by toxic exposures under the PACT Act.
- CyPath® Lung, bioAffinity’s noninvasive lung cancer detection test, will be highlighted for its role in early diagnosis.
- Philips and 4DMedical will present their advanced imaging and diagnostic technologies for lung health assessment.
The big picture
This collaboration underscores the growing focus on early detection and prevention in lung health, particularly for high-risk groups like veterans. The partnership aligns with broader industry trends toward noninvasive diagnostics and AI-driven healthcare solutions, aiming to reduce costs and improve patient outcomes. The webinar serves as a platform to showcase how advanced technologies can address critical gaps in veteran healthcare.
What we're watching
- Regulatory Compliance
- Whether bioAffinity can navigate the evolving regulatory environment for laboratory-developed tests (LDTs) under CLIA oversight.
- Market Expansion
- The pace at which bioAffinity can scale CyPath® Lung adoption among veteran healthcare providers and other high-risk populations.
- Technological Integration
- How Philips and 4DMedical’s imaging technologies will complement bioAffinity’s diagnostic tools in improving lung health screening outcomes.
Related topics